



PORTER & CO. CONFERENCE 2025

A Two Trillion Dollar Biotech-To-Be

Dave Lashmet | Editor, Stansberry Venture Technology

The “Get Rich Slowly” Plan

10 Year Return of ~400% (After Inflation)



- Audited 10 Year Annual Returns of +16.0%
Annual CPI Increase is +2.9%
Net +13.1% Annualized Gains
- Rule of 72:
Divide 72 by 13.1 = Doubles in Five Years
- 1000%+ Gainer in Biotech (Inovio)
- 1000%+ Gainer in Tech (Nvidia)
- **43 Doubles out of 114 total picks**

How You Can Get My Letter:




I've tracked mega-trends in biotech for 10 years:

- Rise of Cancer Immune Therapy
- Rise of Weight Loss Drugs



What's Coming Next is Bigger Than Both...

OBESSE PATIENTS AREN'T JUST LOSING FAT ON GLP-1 DRUGS



THEY'RE ALSO LOSING MUSCLE
*A QUARTER OF WEIGHT LOSS IS
SKELETAL MUSCLE*

MUSCLE LOSS ON GLP-1 TREATMENT

42 year old male patient

BEFORE



AFTER



CAT Scan cross section through gut

5% loss of back muscles


Super-Serum Actually Exists Naturally

**A BELGIAN BLUE STEER
IS ALL MUSCLE**



**Belgian Blues have a broken myostatin gene
So their muscles keep growing**

HOW SUPER SERUM WORKS




It blocks the muscle off switch

Imagine what this means for your local tri-athlon




BIMAGRUMAB BUILDS LEAN MUSCLE



When combined with Wegovy, it helps save lean muscle, and boosts weight loss.

FAT WEIGHT LOST ON SUPER SERUM VS GLP-1




Super serum alone is as good as GLP-1

SIDE EFFECTS OF MUSCLE BUILDING STEROIDS


Severe acne



Blood clots in the lungs



Ruptured tendons



Kidney failure

REGENERON'S ANTIBODY IS A FATAL MISTAKE

Overview of adverse events


	Semaglutide (n=151)	Semaglutide + trevogrumab 200 mg (n=148)	Semaglutide + trevogrumab 400 mg (n=151)	Semaglutide + trevogrumab 400 mg + garetoismab 10 mg/kg (n=149)
Participants with at least one AE, n (%) ^a				
AE	100 (66.2)	105 (70.9)	105 (69.5)	116 (77.9)
Severe AE	2 (1.3)	3 (2.0)	4 (2.6)	21 (14.1)
SAE	1 (0.7)	1 (0.7)	2 (1.3)	14 (9.4)
Treatment-related AE	73 (48.3)	74 (50.0)	88 (58.3)	98 (65.8)
AE leading to study treatment discontinuation	7 (4.6)	7 (4.7)	16 (10.6)	46 (30.9)
AE leading to death ^b	0	0	0	2 (1.3)
AEs occurring in ≥10% of participants in any treatment group ^c				
Muscle spasms	7 (4.6)	9 (6.1)	14 (9.3)	61 (40.9)
Nausea	45 (29.8)	35 (23.6)	53 (35.1)	35 (23.5)
Constipation	24 (15.9)	33 (22.3)	31 (20.5)	22 (14.8)
Diarrhea	15 (9.9)	17 (11.5)	9 (6.0)	13 (8.7)
Vomiting	15 (9.9)	16 (10.8)	16 (10.6)	10 (6.7)

^aNot all participants have completed the 24-week safety follow-up period as of the data cutoff date of 6 June 2025. AEs that occurred in ≥5% of participants in any treatment group included muscle spasms, nausea, constipation, fatigue, diarrhea, headache, vomiting, gastroesophageal reflux disease, upper respiratory tract infection, nasopharyngitis, UTI, influenza and COVID-19. Most of these events were mild to moderate in severity. ^bOne death was due to an undetermined cause in a participant with multiple cardiovascular risk factors and the second due to cardiac arrest in a participant with history of cardiovascular disease, a causal association between treatment and these events has not been identified.

^cAE, adverse event; COVID-19, coronavirus disease 2019; SAE, serious adverse events; UTI, urinary tract infection.

**14X more serious side effects -
ER visits - and 2 deaths**


EVERYONE REBOUNDS AFTER STOPPING GLP-1'S BECAUSE IT SUPPRESSES YOUR APPETITE



Folks Gain Back 2/3rds of lost weight in a year
Even the biggest losers gain back 50%


Weight loss %: ■ <5% ■ <10% ■ <15% ■ <20% ■ <25%

ELI LILLY'S WEIGHT-LOSS PILL



Orforglipron binds to GLP-1

ELI LILLY'S WEIGHT LOSS PILL



**Patients lost 13% body weight
after a year and a half**

949 patients on placebo, 730 patients on orforglipron



BARRON'S

[Stock Picks](#) [Market Data](#) [Watchlist](#) [Magazine](#) [Advisor Center](#) | [Markets](#) [More Topics](#) ▼

[BIOTECH AND PHARMA](#) | [STREET NOTES](#)

Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says

 **Business**

BUSINESS • 2 MIN READ

Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly

SEP 10, 2025 ▼

 **Reuters**

My News




Eli Lilly to invest \$5 billion in new Virginia plant as pharma braces for tariffs

By Sneha S K

September 16, 2025 9:17 AM PDT • Updated September 16, 2025

WEIGHT LOSS WITH ORAL SEMAGLUTIDE



Patients take 25mg of drug every day

102 patients on placebo, 205 patients on oral semaglutide

ELI LILLY IS INVESTING \$50B WORLDWIDE TO BOOST OUTPUT

Pleasant Prairie, WI



Lebanon, IN



Limerick, Ireland



Alzay, Germany




To protect your brain against dementia, start pedaling, study suggests

SEP 20, 2025 ▾

THE NEW SCIENCE OF EXERCISE


Four Repair Signals Built by Muscles




Brain Balm
(Irisin)



Vein Balm
(C-type
Natriuretic
Peptide)




Muscle Balm
(Musclin)



Heart Balm
(Atrial Natriuretic
Peptide)

MICROGLIAL CELLS EAT BETA-AMYLOID PLAQUE


■ Microglial cell ■ Beta-amyloid plaque




And rebuild the blood-brain barrier

KISUNLA CLEARS BRAIN PLAQUE

Before treatment




After treatment



And slows Alzheimer's disease
Results in an 80 year old man

KEY FINDING: KISUNLA WORKS



The longer you take it, the more it helps

Eli Lilly (NYSE: LLY) Will Triple by 2030, Thanks to Super-Serum, A Weight Loss Pill, and This Alzheimer's Antibody

How You Can Get My Letter:



David Lashmet | March 11, 2024

How to Profit - and Keep Profiting - From the GLP-1 Revolution

One class of drugs is changing the world...

If you've been watching the news, you know what I'm talking about... safe and effective weight-loss drugs.

These drugs are already helping thousands of Americans. Soon, it'll be millions.


You see, Americans are growing and growing in the wrong direction...

In 1980, 12% of American adults - 1 in 8 people - were obese. Today, 42% of American adults - nearly half - are obese, and 9% of adults are morbidly obese. And it's not just the U.S. The rest of the developed world - including the U.K., Europe,


Thank you



Two Revolutionary Changes in Weight Loss Drugs



ELI LILLY IS INVENTING FASTER, CHEAPER WAYS TO BUILD ITS 2026 BLOCKBUSTER DRUG



It's still a work in progress